Celltrion Remsima SC Achieves 26% Market Share in Europe... Strong Performance for Both New and Existing Products

Accelerating Sales Drive a Performance Turnaround

Celltrion's autoimmune disease and cancer treatment drugs, currently being sold in Europe, continue to maintain strong prescription momentum and solidify their market position. Alongside stable prescription performance for its flagship products, newly launched high-margin products from last year have also shown steady order growth from the outset, raising expectations for performance driven by both new and existing products.

According to pharmaceutical market research firm IQVIA on February 3, Celltrion's flagship autoimmune disease treatment, the Remsima product line (IV and SC), recorded a combined market share of about 68% in Europe as of the third quarter of last year, maintaining a commanding lead in prescriptions. Both intravenous and subcutaneous formulations are showing stable prescription trends, with remarkable market shares across Europe, including 81% in France, 84% in the United Kingdom, and 74% in Germany, as well as in the five major EU countries (EU5).

Celltrion's autoimmune disease treatment product, Remsima SC. Celltrion

In particular, the growth of Remsima SC, the world's only infliximab subcutaneous injection treatment, stands out. Remsima SC, an infliximab formulation, has demonstrated significant therapeutic effects in the field of inflammatory bowel disease (IBD) compared to other agents, based on real-world clinical data. Its greatly improved dosing convenience has led to high preference among both physicians and patients.

On the back of this product competitiveness, Remsima SC continued its growth in Europe, achieving a 26% market share in the most recent quarter, up 2 percentage points from the previous quarter. In some European countries, it recorded the highest prescription volume among infliximab products, maintaining the number one market share in major European countries such as Germany (48%), Finland (58%), Bulgaria (56%), Croatia (43%), and the Czech Republic (42%).

Another of Celltrion's autoimmune disease treatments, 'Yuflyma' (active ingredient: adalimumab), also maintained the number one spot in prescriptions in Europe during the same period with a 24% market share. In a fiercely competitive landscape with a total of nine adalimumab products, including the original, Yuflyma has delivered outstanding results in major European countries such as Italy (53%) and the United Kingdom (42%), further strengthening its market influence.

Meaningful achievements are also being sustained in the oncology sector. Vegzelma (active ingredient: bevacizumab), a treatment for metastatic colorectal cancer and breast cancer, held the number one position in prescriptions in Europe during the same period with a 26% market share. Despite being a latecomer, launched nearly four years after competing products and facing challenges in securing supply channels, Celltrion has maintained the top spot since the end of 2024 by leveraging a tailored direct sales strategy based on the characteristics of each national market and the strong preference for the Celltrion brand.

Celltrion's autoimmune disease treatment, 'Yuflyma'. Celltrion

While existing products continue to grow, Celltrion's recently launched high-margin new products are also delivering strong results from the outset, raising expectations for early market leadership.

First, Omliclo (active ingredient: omalizumab), a treatment for chronic spontaneous urticaria launched in Europe in September last year, secured about 70% of the local omalizumab market by winning multiple hospital group tenders in the Netherlands. For Idencelt (active ingredient: aflibercept), an ophthalmology treatment launched in December last year, Celltrion succeeded in securing an early supply base in the United Kingdom, a major European country, by winning National Health Service (NHS) tenders for England, Scotland, and Northern Ireland immediately upon launch.

Additionally, the most recently launched autoimmune disease treatment, Aptozma (active ingredient: tocilizumab), secured about 80% of the local private market by winning the majority of private hospital group tenders in France. In Spain, the product has also achieved early results by winning regional public tenders and being selected as a supply product for INGESA, the procurement agency under the Ministry of Health.

A Celltrion official stated, "Our flagship products, led by the Remsima product line, are recording stable sales based on Celltrion's differentiated competitiveness, which is built on country-specific direct sales strategies and strong brand preference. With the experience and know-how accumulated over years of direct sales in biopharmaceuticals, our newly launched high-margin products are also rapidly delivering results from the outset. We will make every effort to further expand the performance of both new and existing products across Europe and achieve a turnaround in results."

This content was produced with the assistance of AI translation services.